Handelsavisen has updated its investment thesis for China Pharma Holdings Inc (CPHI.K) following an internal sector classification audit.
The revision stems from a sector-fix batch process that identified and corrected contamination in the company’s industry tagging, ensuring alignment with direct GICS classification paths.
The data integrity check, completed on July 13, 2026, triggered a re-analysis of the firm’s sector attributes.
This correction is material for readers tracking the company’s peer group and sector-specific performance metrics, as previous tagging may have misaligned the stock with its true industry peers.
In Handelsavisen’s own analysis, China Pharma Holdings holds a composite score of 62.7/100.
The updated sector classification ensures that this score is benchmarked against the correct set of pharmaceutical and healthcare peers, rather than a contaminated or broader index.